Puzzling Over the Hurt Down-Under
Serious Mental Illness and Contraception
New 13-Cycle Vaginal Contraceptive System
The Future of Family Planning in Post-COVID America
New ASCCP Guidelines: Implications for FP
On the alert: mood disorders during 2020 stressors
Challenges old and new during the pandemic
Reproductive health in the time of Covid-19
Missed Pills: The Problem That Hasn’t Gone Away
Find the “yes! . . . and” rather than “no” or “but”
Digital Family Planning: the Future is Now
Irregular Bleeding Due to Contraceptives
Ouch! Best approaches to menstrual pain
Contraceptive efficacy: understanding how user and method characteristics play their part
Strategizing treatment for chronic heavy menstrual bleeding
Untangling the literature on obesity and contraception
High tech apps for no-tech FABM
Menstrual exacerbation of other medical conditions
From Princeton University: Thomas James Trussell (1949-2018)
The Short and Long of IUD Use Duration
Selecting a Method When Guidance Isn’t Clear-cut
Healthcare in the Time of Digital Expansion
The Scoop on Two New FDA-Approved Contraceptive Methods
Pregnancy of unknown location—meeting the challenge
Big “yes” (with caveats) to CHCs during perimenopause
The role of IUDs (LNG IUDs, too!) in emergency contraception
Combined pills’ effect on mood disorders
Abortion in the U.S.: safe, declining, and under threat
Hope for ovarian cancer screening test
Breast cancer still a small risk with some hormonal contraceptives
Record rate of HPV-related throat cancer
Viruses in semen potentially transmissible
Don’t Abstain from Your Role in Abstinence
Teens births declining but geographic ‘hotspots’ defy trend
Online Medical Abortion Service Effective and Safe
Do Women Really Need to Wait That Long?
Reassuring news on depression and OC use
PMDD: Genetic clues may lead to improved treatment
Breast cancer risk when there is a family history
Body weight link to breast and endometrial cancers (and 11 others)
Family Planning in 2017 and Beyond
Make Me Cry: Depression Link (Again)?
Managing implant users’ bleeding and spotting
Zika: Updated guidance for providers
Pharmacist-prescribed contraceptives
Hot off the press! 2016 MEC and SPR
Zika virus fears prompt increased request for abortion in nations outlawing abortions
Opioid use epidemic among reproductive-age women
Good news on the family planning home front!
War Against Planned Parenthood Hurts Women
Win-win for both treatment and prevention
Menopause, mood, mental acuity, and hormone therapy
Emergency contraception for teens
Postpartum Contraception: Now, Not Later
Are we practicing what we preach?
Be alert to VTE in hormonal contraceptive users
LARC among teens increased 15-fold, but not enough
Brain cancer and hormonal contraception
Free tools: Easy access to the US Medical Eligibility Criteria for Contraceptive Use
Alcohol consumption when pregnancy is unwanted or unintended
Latest Data on Contraceptive Use in the United States
LateBreaker sampler from Contraceptive Technology conference
Emergency Contraceptive Pill Efficacy and BMI/Body Weight
Handout on Unintended Pregnancy and Contraceptive Choice
Ask About Withdrawal (Really!)
Rules to Practice By: Safety First and Cleanliness is Close to. . .
What’s Vanity Fair Got Against the NuvaRing?
Promising New Treatment for Hepatitis C
Numbers matter, so make them simple for patients
The Recession’s Effect on Unintended Pregnancies
Lessons Learned from the Contraceptive CHOICE Project: The Hull LARC Initiative
Applying the “New” Cervical Cytology Guidelines in Your Practice
Acute Excessive Uterine Bleeding: New Management Strategies
Medical indications for IUD use in teens

Many people get their health news from the media, which may relay information that is incorrect or, more often, incomplete. Anyone who checks the news or social media, or any media for that matter, has learned about Charlie Sheen—HIV-infected but with undetectable levels of virus in his serum—and how he had condom-less sex with a couple of partners. However, those reports failed to educate readers and viewers about the risks and protections for HIV transmission.
The National Institutes of Health recently reported on the very low risk of HIV transmission from someone receiving antiretroviral therapy. Good news, undoubtedly—a win-win both for treatment of an infected individual and for prevention of transmission to an uninfected partners. But how should a HIV-uninfected partner be counseled regarding risk if she or he may have a treated partner with undetectable HIV-load?
Beginning in 2005, NIH enrolled 1,763 heterosexual discordant couples in Botswana, Brazil, India, Kenya, Malawi, South Africa, Thailand, the United States, and Zimbabwe. One partner was HIV-infected and the other HIV-uninfected. The HIV-infected partners were randomly assigned to either start antiretroviral therapy (ART) right away (early) or to delay until they developed symptoms. Subjects in both groups were counseled in safer sex practices and to use condoms, which were provided at no cost. Although the randomized control study was stopped in 2011 to offer immediate ART treatment to all HIV-infected persons (because treatment was so effective in preventing transmission),[1] the study was not complete until 2015. In the final analysis, NIH reported that early ART treatment reduced HIV transmission by 93%.[2] [3] Among the HIV-infected study participants who delayed taking ART, 43 of their partners became newly infected. But among the study participants who started ART early, only 8 cases of transmission occurred, with half most likely occurring before treatment had fully suppressed HIV replication. The other cases were thought to occur because the treatment was not taken as prescribed or because a partner’s HIV strain was resistant to the treatment.
Terrific news. ART treatment offers even better protection than does condom use alone with HIV-infected partners. But that is not the entire story, and uninfected partners need to be fully informed. First, undetectable levels of virus do not equate with the absence of virus. The only persons in whom HIV is absent are those who are not infected with the virus to begin with. So what undetectable means is that when the serum is checked, the virus resides at less than 40-75 copies of the virus per ml of blood. It indicates the level of virus load at the time of testing only, not during the time between tests, so it is possible the viral load may increase without the infected person knowing it. ‘Undetectable’ also does not mean that the virus is absent in other body fluids such as semen or vaginal discharges. Further it is thought that co-infection with another STD may boost the HIV load in genital fluids. (See https://www.aids.gov/hiv-aids-basics/just-diagnosed-with-hiv-aids/understand-your-test-results/viral-load/)
What an undetectable level does indicate is that the HIV-infected individuals have been taking ART as prescribed, are healthy, and have good immune system response. With fewer copies of HIV in their bodies, they present fewer opportunities to transmit the virus to their uninfected partners. And in regard to the participants in the NIH study of heterosexual discordant couples, the 93% reduction in transmission risk was seen only among those couples in which the HIV-infected partner had been consistently taking ART as prescribed and also maintained a consistently undetectable HIV load.
What would an informed uninfected partner need to know?
- Use condoms. Condom use further reduces your risk of HIV, even if your HIV-infected partner is taking ART and has an undetectable viral load.1
- Are you, as an uninfected partner, taking or planning to take pre-exposure prophylaxis (PrEP), which also reduces risk, though not to zero. (Mr. Sheen said two women, with whom he had condom-less sex, had opted to take PrEP.[4])
- Is your HIV-infected partner taking ART? Consistently and as prescribed?
- When was your HIV-infected partner’s last test of viral load?
- Does your HIV-infected partner possibly have another STD, too?
For individually tailored information, consult the HIV Risk Reduction Tool developed by the Centers for Disease Control and Prevention: https://wwwn.cdc.gov/hivrisk/
For another potential win-win scenario, a new randomized study (HPTN 074) has begun enrollment in Indonesia, Ukraine, and Vietnam to test integrated treatment and prevention for people who inject drugs. Index participants have HIV viral loads greater than 1,000 copies/mL at screening, and their partners will be uninfected.
—Deborah Kowal, MA, PA, Executive editor of Contraceptive Technology
—Ward Cates, Jr., Distinguished Scientist and President Emeritus, FHI 360, Durham North Carolina
[1] Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365:493-505.
[2] National Institute of Allergy and Infectious Diseases. HIV control through treatment durably prevents heterosexual transmission of virus. Press release, July 20, 2015. Accessed Jan 22 2016: http://www.niaid.nih.gov/news/newsreleases/2015/Pages/HPTN052results.aspx
[3] National Institute of Allergy and Infectious Diseases. News & events. Questions and answers. The HPTN 052 study: preventing sexual transmission of HIV with anti-HIV drugs. July 20, 2015. Accessed Jan. 22 2016 at http://www.niaid.nih.gov/news/QA/Pages/HPTN052qa.aspx
[4] Kaufman D. Can Charlie Sheen really have doctor-approved unprotected sex? New York Post, Nov. 17, 2015. Accessed Jan. 22 2016 at https://www.aids.gov/hiv-aids-basics/just-diagnosed-with-hiv-aids/understand-your-test-results/viral-load/